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Abstract  
 
The co-existence of stroke and HIV has increased in recent years, but the impact of HIV on 
post stroke outcomes is poorly understood. We examined the impact of HIV on inpatient 
mortality, length of acute hospital stay and complications (pneumonia, respiratory failure, 
sepsis and convulsions), in hospitalised strokes in Thailand. All hospitalised strokes between 
1st October 2004 and 31st January 2013 were included. Data were obtained from a National 
Insurance Database. Characteristics and outcomes for non-HIV and HIV patients were 
compared and multivariate logistic and linear regression models were constructed to assess 
the above outcomes. Of 610,688 patients (mean age 63·4 years, 45·4% female), 0·14% (866) 
had HIV infection. HIV patients were younger, a higher proportion were male and had higher 
prevalence of anaemia (p<0·001) compared to non-HIV patients. Traditional CV risk factors, 
hypertension and diabetes, were more common in the non-HIV group (p<0·001). After 
adjusting for age, sex, stroke type and co-morbidities, HIV infection was significantly 
associated with higher odds of sepsis (OR 1·75;1·29-2·4), and inpatient mortality (2·15;1·8-
2·56) compared to patients without HIV infection. The latter did not attenuate after 
controlling for complications (2·20;1·83-2·64). HIV infection is associated with increased 
odds of sepsis and inpatient mortality after acute stroke. 
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Introduction 
The incidence of stroke in low to middle income countries where HIV is prevalent has 
increased by over 100% during the past four decades [1]. Co-existence of HIV and stroke has 
increased and associations between HIV and stroke have been increasingly recognised [2,3]. 
Indeed, both these conditions are leading causes of death and disability globally, and thus 
their increasing co-existence is of significant public health relevance [4]. An independent 
association between HIV and ischaemic stroke has been demonstrated and, in some cases, 
stroke has been the presenting manifestation of HIV [5-7]. 
Despite this, the impact of HIV on stroke outcome is poorly understood. In particular, 
the prognostic implications of HIV on stroke have never been specifically investigated. With 
advances in HIV treatment associated with improved survival rates, the population ageing 
with HIV will continue to grow with a likely increasing incidence of non-communicable 
conditions including stroke. 
We investigated the characteristics and prognostic implications of stroke patients with 
co-existing HIV infection in Thailand. Serious and common complications, inpatient 
mortality and length of acute inpatient hospital stay (LOS) after stroke were the selected 
outcomes of interest.  
 
Methods 
Data were obtained from the Universal Coverage Health Security Insurance Scheme 
Database in Thailand. Briefly, in Thailand, the whole population is covered by three 
insurance schemes: the Civil Servant Benefit System covers government employees and their 
dependants (~7% of the population). The Social Security scheme covers private sector 
employees (~13% of the population). The Universal Coverage Health Security Scheme is a 
basic health insurance scheme covering the rest of the population [8]. 
All acute hospitalised strokes in Thailand between 1st October 2004 and 31st January 
2013 were studied. We selected this time period as stroke management in Thailand has 
become more in line with current international practice since 2004. Diagnosis of stroke was 
identified from ICD coding (ICD10 I60-I64) on reimbursement forms. In Thailand, diagnosis 
of stroke is made during individual's inpatient hospital stay by attending clinical teams based 
on clinical features and investigation findings including brain imaging. Demographic and 
clinical data were obtained from reimbursement forms using ICD codes, on an annual basis, 
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from 2004 until 2013. Data included age, sex, HIV status, co-morbidities, stroke type, 
complications of stroke occurring during hospital admission (pneumonia, sepsis, respiratory 
failure and convulsions (using ICD codes)), admission and discharge date and inpatient 
mortality. Stroke types were categorised as haemorrhagic (I61,I62), ischaemic (I63) or stroke 
of undetermined pathology (I64).  
Statistical analysis was performed using Stata 11·2/SE (Texas, USA). Statistical 
significance was assumed where p<0·05. Descriptive statistics were calculated separately for 
individuals with and without HIV infection and compared.  
Post stroke complications for stroke patients with HIV were assessed using four 
logistic regression models using non-HIV patients as the reference category. Model A 
presents an unadjusted analysis, model B adjusted for age and sex, model C adjusted for age, 
sex and stroke type, model D was constructed as in model C with additional adjustment for 
the three commonest co-morbid conditions (hypertension, history of previous stroke and 
anaemia), and model E (mortality and LOS outcomes only) was constructed as in model D 
with additional adjustment for complications of stroke (pneumonia, sepsis, respiratory failure 
and convulsions). Models were repeated stratifying by stroke type. For LOS outcome a linear 
regression model was used, but in order to allow for the non-normal distribution of LOS the 
bootstrap using 1,000 replications was used to estimate the p-value and confidence interval 
for the mean difference in LOS between HIV and non-HIV stroke patients. 
The study was approved by the Ethics Committee in Human Research, Khon Kaen 
University, Khon Kaen, Thailand. 
 
Results 
Between 1st October 2004 and 31st January 2013, 610,688  hospitalised stroke patients 
were identified and included in this analysis. Sample mean age was 63·4 years (±14·7 years), 
45·4% (N=276,178) were female and the prevalence of HIV was 0·14% (N=866). 
Characteristics of the study sample, according to HIV status, are presented in Table 1. On 
average, those with HIV were 22·2 years younger and a higher proportion were male 
(p<0·001). Hypertension and diabetes were almost five times more prevalent in the non-HIV 
group (p<0·001) but the overall number of patients with diabetes in the HIV group was very 
low (N=29). The prevalence of anaemia in the HIV group was more than double than in the 
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non-HIV group (p<0·001). The proportion of individuals with different types of stroke varied 
between the two groups (p<0.001). Haemorrhagic stroke was marginally more common in 
the non-HIV group whilst ischaemic stroke was more common in the HIV group. The 
prevalence of stroke of undetermined pathology was almost double in the non-HIV group 
compared to that in the HIV group. 
The commonest complications of stroke in this cohort were pneumonia, sepsis, 
respiratory failure and convulsions, and were therefore selected as outcomes of interest 
(Table 2). Overall, stroke complications were more prevalent in the HIV group, apart from 
pneumonia (p=0·009) and there was no significant difference in rates of respiratory failure 
(p=0·48). The remaining complications sepsis, convulsions and inpatient death were 
significantly more prevalent in the HIV group (p=0·004, p<0·001, p<0·001, respectively). 
Mean LOS was 20% greater in the HIV group compared to the non-HIV group (p=0·002).  
Odds ratios (OR) and corresponding 95% CI for complications of stroke in patients 
with HIV are detailed in Table 3. Similarly, the analysis stratified by stroke type is presented 
in Table 4. After full adjustment, HIV was associated with higher odds of sepsis and 
mortality (ORs 1·75 (1·29-2·4) and 2·15 (1·8-2·56)). Additionally, controlling for 
complications did not attenuate the poor mortality outcome (2·20; 1·83-2·64). HIV was 
associated with a higher risk of convulsions in earlier models, in haemorrhagic and ischaemic 
stroke, but the associations observed did not reach statistical significance after adjustments. 
Overall, HIV was associated with longer LOS but only model C reached statistical 
significance. However, in the stratified analysis, HIV had a higher odds of longer inpatient 
stay in ischaemic stroke (OR 2.74 (1.8-3.68)).  
  
Discussion 
Our study is the largest analysis to date of the clinical characteristics and outcomes of 
hospitalised strokes in patients with HIV. In line with previous reports, stroke patients with 
HIV were younger and a higher proportion were male, compared to those without HIV 
infection [2,6,9,10]. Traditional stroke risk factors were more prevalent in the non-HIV 
group, whilst anaemia was more prevalent in the HIV group [11]. We demonstrate a higher 
rate of post-stroke complications in patients with HIV and, to our knowledge, are the first 
group to specifically report this. HIV infection had an impact on the likelihood of developing 
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sepsis during acute hospital stay after stroke and was associated with increased inpatient 
mortality. 
The lower prevalence of traditional stroke risk factors in our HIV cohort supports 
literature suggesting that the mechanisms and risks of stroke in HIV are different from the 
general population. These include combination antiretroviral therapies (cARTs), chronic 
systemic and opportunistic infections, vasculopathies, coagulopathies and metabolic and 
immune dysregulation [12,13]. As previously reported, ischaemic stroke was the commonest 
type of stroke in patients with HIV [2,5,10]. It is perhaps surprising that the prevalence of 
stroke of undetermined pathology was higher in the non-HIV group. In HIV, neurological 
complications e.g. cerebral toxoplasmosis, are common and may mimic stroke. These 
alternative diagnoses, with different treatment requirements, should always be considered in 
HIV patients with suspected stroke.  
Our HIV cohort had a higher incidence, and in some cases risk, of convulsions, sepsis, 
inpatient mortality and longer LOS than those patients without HIV. Convulsions were 
almost twice more frequent in the HIV group although the fully adjusted ORs were not 
statistically significant. In a much smaller sample Hoffman et al. observed a higher 
prevalence of seizures on admission in stroke in HIV, but this was not  [14]. Our findings 
related to increased likelihood of sepsis in HIV compared to non-HIV infected stroke patients 
(fully adjusted OR 1·75) are not surprising. This is important because acute inflammatory 
response and sepsis, in the acute stroke setting, are associated with poorer outcomes [15,16]. 
Our finding is also in keeping with reports of co-existent and causative infection in ischaemic 
stroke in HIV [10,14,17].  It is not clear why those with haemorrhagic stroke were at highest 
risk of sepsis (OR 2·16). It may be because haemorrhagic strokes present with more severe 
neurological deficit, requiring invasive treatment entailing a higher infection risk. 
The higher risk of mortality in stroke in HIV (fully adjusted OR 2·20) has previously 
been found, but is not consistent with all literature [10,11,18]. These smaller single centre 
studies may have lacked power to detect statistically significant findings. Differences in 
results may also reflect the increasing availability of cARTs over time, or changes in acute 
stroke treatment [10]. Our finding is important because since the genesis of cART, non-HIV 
related conditions, including cardio and cerebrovascular disease, have become the leading 
causes of death in people with HIV infection [19]. It is interesting that ischaemic stroke of 
undetermined pathology in HIV carried the highest risk of death (OR=4·12), raising the 
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possibility of serious life threatening causes of stroke in these cases. Unfortunately, data on 
precise cause of death, was not available from our data set and so was not accounted for in 
this analysis. In keeping with the higher prevalence of complications found here, and with 
previous literature, mean LOS was longer in HIV patients, particularly those with ischaemic 
stroke [11].  
Overall this study shows that HIV in stroke has poorer clinical outcomes. We found 
that, compared to non-HIV stroke patients, HIV patients with stroke are younger and have 
different co-morbid conditions which may contribute to risk of stroke in HIV and subsequent 
clinical sequalae. Alternatively, there may be a broader spectrum of stroke severity in older 
non-HIV stroke patients and that HIV patients suffer more severe stroke at a younger age, with 
higher complication rates. Our dataset did not allow us to investigate this, but another group 
have reported greater stroke severity in HIV whilst others have found no differences [9,10,18]. 
Another explanation for our findings may be the aetiology of stroke in HIV. Reported 
aetiologies of stroke in HIV e.g. vasculopathies may incur more widespread arterial 
involvement and hence worsen outcomes [10,20]. To this end, our findings and those in 
reported literature reinstate that stroke in HIV is a complex issue. 
 Our study has some limitations that should be acknowledged. Firstly, we relied on 
ICD coding to identify diagnosis of stroke and co-morbidity data, including HIV. Secondly, 
our data source meant that detailed clinical information e.g. stroke severity and pre-stroke 
disability, which are important determinants of outcomes were not available [21]. Thirdly, we 
did not have data on cART therapies, which may impact stroke outcome. However, cART 
therapies have been widely available free of charge throughout Thailand since 2002 [22]. 
Fourthly, we were not able to study mild strokes not admitted to hospital and very severe 
strokes resulting in death prior to admission. However, the truncation of distribution is only 
likely to attenuate the results.  
Notwithstanding these limitations this work makes an important contribution to 
understanding of outcomes of stroke in HIV. The use of reimbursement forms as a data set 
allowed us to capture an almost actual population service use for stroke in Thailand and to 
study a large nationwide, unselected population and availability of outcome data was 
complete.  
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Conclusions 
In conclusion, the findings confirm that the characteristics of stroke in patients with 
HIV are different from those in the general population and show that the prevalence, and in 
some instances risk, of sepsis, convulsions, inpatient mortality, and longer LOS stroke are 
higher in patients with HIV. Foresight and prompt treatment of these complications, and any 
co-existing illnesses, could potentially help improve outcomes of stroke in people with co-
existing HIV infection. Future studies should focus on fully establishing risk factors and 
mechanisms of stroke in HIV, and developing optimal treatment strategies for stroke in HIV.  
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 Table 1: Sample characteristics of 610,688 hospitalised stroke patients with and without HIV 
infection in Thailand (2004-2013)  
Characteristic Non-HIV  HIV  P value 
Number (N) 609,802 866  
 
Age (years)   
 
 
Mean (± SD) 63·5 (14·7) 41·3 (11·3) 
 
<0·001 
 
Female sex % (N) 45·2 (275,911) 30· 8 (267) 
 
<0·001 
 
Co-morbidities % (N)   
 
 
Hypertension 44·2 (269,562) 9 (78) 
 
<0·001 
 
Diabetes  16·5 (100,319) 3·3 (29) 
 
<0·001 
 
Previous stroke  7·8 (47,467) 7·4 (64) 
 
0·666 
 
Anaemia  5·4 (32,652) 12·9 (112) 
 
<0·001 
 
Rheumatic heart disease  0·9 (5,488) 0·3 (3) 
 
0·085 
 
Chronic obstructive pulmonary 
disease 1·9 (11,591) 0·3 (3) 
 
0·001 
 
Chronic ischaemic heart disease  2.7 (16,344) 0 (0) 
 
<0·001 
 
Chronic kidney disease 3·1 (19,188) 0·7 (6) 
 
<0·001 
 
Atrial fibrillation 6·1 (37,177) 0·7 (6) 
 
<0·001 
 
Heart failure 1·5 (8,994) 0·7 (6) 
 
0·056 
    
 
Stroke type % (N)   
 
<0·001 
  
Haemorrhagic 34·6 (211,117) 30.1 (261) 
 
  
Ischaemic 50·1 (305,621) 61.3 (531) 
 
  
Stroke of undetermined pathology 15·3 (93,061) 8·5 (74) 
 
  
 Table 2: Comparison of outcomes after stroke in 610,688 hospitalised stroke patients with 
and without HIV infection in Thailand (2004-2013) 
 
Outcome investigated  Non-HIV HIV P value 
 
Number (N) 609,802 866 
 
 
 
Complication of stroke % (N)   
 
 
Pneumonia 9·6 (58,524) 7·2 (62) 
 
0·015 
 
Sepsis 3.2 (19,654) 5 (43) 
 
0·004 
 
Respiratory failure 7·3 (44,333) 6·7 (57) 
 
0·436 
 
Convulsion 3·4 (20,475) 6·4 (55) 
 
<0·001 
 
Inpatient death 
 
13·3 (80,977) 
 
20·2 (175) 
 
<0·001 
 
Length of inpatient stay (days)   
 
 
 
Mean (± SD) 7·5 (11·5) 9 (10·6) 
 
0·2909 
 
 Table 3: Odds ratios and corresponding 95% CI (mean LOS differences and 95%CI for LOS outcome) for complications of hospitalised stroke 
in 866 patients with HIV using 609,802 non-HIV patients as the reference category in Thailand (2004-2013) 
 Odds ratio (95% confidence interval)  
Complication Model Aa Model Bb Model Cc Model Dd Model Ee 
Pneumonia 0.73 (0.56,0.94) 1.14 (0.88,1.48) 1.21 (0.93,1.57) 1.01 (0.78,1.32)  
Sepsis 1.57 (1.15,2.13) 2.16 (1.59,2.95) 2.17 (1.6,2.96) 1.75 (1.29,2.4)  
Respiratory failure 0.9 (0.69,1.18) 1 (0.76,1.31) 1.16 (0.88,1.52) 1.02 (0.78,1.35)  
Convulsion 1.95 (1.48,2.57) 1.29 (0.98,1.7) 1.23 (0.94,1.62) 1.05 (0.8,1.38)  
Death 1.65 (1.4,1.95) 1.65 (1.4,1.95) 2.29 (1.92,2.73) 2.15 (1.8,2.56) 2.2 (1.83,2.64) 
Mean difference in length of 
inpatient stay (days) 
1.54 (0.84,2.24) 1.55 (0.85,2.25) 2.05 (1.30,2.79) 1.64 (0.89,2.39) 1.11(0.41,1.82) 
 
aModel A= unadjusted analysis 
bModel B=analysis adjusted for age and sex 
cModel C=analysis adjusted for age, sex and stroke type 
dModel D=analysis adjusted for age, sex, stroke type and co-morbidities 
eModel E = analysis adjusted for age, sex, stroke type, co-morbidities and complications (Pneumonia, sepsis, respiratory failure or convulsion)
 Table 4: Odds ratios and corresponding 95% CI (mean LOS differences and 95%CI for LOS outcome) for complications of hospitalised stroke 
in 866 patients with HIV stratified by stroke type using 609,802 non-HIV patients as the reference category in Thailand (2004-2013) 
   
Stroke type Pneumonia Sepsis Respiratory 
failure 
Convulsion Death Length of inpatient 
stay 
Haemorrhagic       
Model Aa 0.6 (0.38,0.95) 1.86 (1.14,3.05) 1.06 (0.74,1.53) 1.88 (1.13,3.12) 1.6 (1.24,2.06) -1.03 (-2.33,0.27) 
Model Bb 0.8 (0.51,1.26) 2.23 (1.36,3.65) 1.21 (0.84,1.74) 1.23 (0.74,2.04) 1.82 (1.41,2.34) -0.81 (-2.07,0.46) 
Model Cc 0.71 (0.44,1.12) 1.9 (1.15,3.14) 1.14 (0.79,1.65) 1.06 (0.64,1.77) 1.76 (1.37,2.27) -1.28 (-2.53,-0.03) 
Model Dd - - - - 1.71 (1.32,2.23) -0.88 (-2.19,0.43) 
       
Ischaemic       
Model Aa 0.77 (0.56,1.07) 1.34 (0.89,2.01) 0.77 (0.5,1.16) 2.03 (1.45,2.84) 1.98 (1.55,2.54) 2.84 (1.90,3.78) 
Model Bb 1.66 (1.19,2.31) 2.25 (1.49,3.4) 1.23 (0.81,1.88) 1.42 (1.01,1.98) 3.16 (2.46,4.05) 3.50 (2.56,4.44) 
Model Cc  1.3 (0.93,1.82) 1.72 (1.14,2.61) 0.98 (0.65,1.5) 1.19 (0.85,1.66) 2.72 (2.12,3.5) 2.99 (2.05,3.93) 
Model Dd - - - - 2.97 (2.27,3.89) 2.74 (1.80,3.68) 
       
Undetermined 
stoke type 
      
Model Aa 0.98 (0.36,2.67) 1.61 (0.39,6.56) 0.65 (0.09,4.66) 1 (0.24,4.06) 3.09 (1.54,6.22) 1.61 (0.09,3.14) 
Model Bb 2.49 (0.9,6.87) 2.89 (0.71,11.86) 1.07 (0.15,7.75) 0.66 (0.16,2.69) 4.71 (2.34,9.51) 2.37 (0.87,3.86) 
Model Cc  2.18 (0.79,6.02) 2.54 (0.62,10.44) 1.01 (0.14,7.28) 0.62 (0.15,2.53) 4.36 (2.15,8.8) 2.30 (0.83,3.77) 
Model Dd - - - - 4.12 (1.96,8.66) 1.92 (0.46,3.38) 
 
aModel A= unadjusted analysis 
bModel B=analysis adjusted for age and sex 
cModel C=analysis adjusted for age, sex and co-morbidities  
dModel D = analysis adjusted for age, sex, stroke type, co-morbidities and complications (pneumonia, sepsis, respiratory failure, convulsions 
 
